Processa Pharmaceuticals, Inc. (PCSA) research
Processa Pharmaceuticals, Inc.- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $1.61
- As of
Processa Pharmaceuticals, Inc. (PCSA): 1 institutional manager tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 10-Q filed 2026-08-14.
As of . Source: SEC EDGAR filings for PCSA. Method and limitations.
Share the PCSA intelligence card
See the full PCSA dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for PCSA on one page. Preview it with sample data, then open it live with a free account.
Preview the PCSA dossierActive signals for PCSA
- mediumNEW_POSITION
CITADEL ADVISORS LLC new position in PCSA
- mediumEARNINGS_BEAT
Q1-2025: Beat consensus by 61.8% - EPS $-7.5 vs $-19.635 estimate
- mediumEARNINGS_MISS
Q2-2025: Missed consensus by 6.6% - EPS $-6.25 vs $-5.865 estimate
- mediumEARNINGS_BEAT
Q3-2025: Beat consensus by 14.2% - EPS $-1.75 vs $-2.04 estimate
- mediumEARNINGS_MISS
Q4-2025: Missed consensus by 68.0% - EPS $-2.57 vs $-1.53 estimate
FREE, NO ACCOUNT
Every signal on PCSA, as it fires
You are seeing 5 of 9 signals recorded on PCSA since 2026-06-02.
The five above landed across 2 days. The other 4 were recorded on 1 other days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in PCSA (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| CITADEL ADVISORS LLCCUSIP 74275C403 · 2026Q2 | $41K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, PCSA
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
PCSA against its peers
PCSA's return on equity of -243.2% ranks in the 18th percentile of 19 Biotechnology sub-industry peers, fiscal periods ending between 2025-06-30 and 2026-04-30.
| Metric | PCSA | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | n/a | 405000 | n/a | 15 |
| Revenue YoY | n/a | -39.9% | n/a | 5 |
| Gross margin | n/a | 35.3% | n/a | 7 |
| Operating margin | n/a | -567.9% | n/a | 12 |
| Net margin | n/a | -467.8% | n/a | 12 |
| Return on equity | -243.2% | -135.5% | 18 | 19 |
Peers (22): NCNA, ONCO, XBIO, CANF, DRMA, EMMA, SNGX, CDIO, KAPA, GRI, ACXP, HEPA, PULM, PMCB, BGMS, EVGN, SXTP, APTOF, AAGH, RVPH, CSCIF, ADTX. Left out: ADAPY (no annual filing), XTLB (period gap), LIMN (no annual filing). Fiscal periods ending between 2025-06-30 and 2026-04-30. Every figure is one full fiscal year read from one annual filing (PCSA: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
See more PCSA signals as they fire
Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to PCSAand get the insider, 13F, options, and confluence read in one view.